MK-677

MK-677, or ibutamoren mesylate, is not a peptide. It is a small molecule taken by mouth that binds the growth hormone secretagogue receptor and mimics ghrelin, and it sits alongside injectable compounds mainly because it is sold in the same places.

What it does to the endocrine axis is well established: daily oral administration raises growth hormone and IGF-1 in older adults while preserving the natural pulsatile release pattern. What three randomised placebo-controlled trials could not show is that the rise carries through to strength or physical function. One of those trials was stopped early after a congestive heart failure signal, and that is the stated reason the US Food and Drug Administration places the substance in category 2 under both compounding pathways. It is also named on the World Anti-Doping Agency Prohibited List.

Ibutamoren mesylate was designed at Merck and published in 1995 as an orally active growth hormone secretagogue. The design paper describes a deliberately non-peptide molecule built to survive being taken by mouth, which is the property that separates it from every injectable compound it gets shelved beside.

It acts on the growth hormone secretagogue receptor, the same receptor used by the hormone ghrelin. That makes it a ghrelin mimetic rather than a growth hormone analogue: it asks the pituitary to release more of its own hormone rather than supplying hormone from outside.

The distinction matters for reading anything written about it. Peptide framing carries assumptions about how a compound is given, about immunogenicity, and about which regulatory categories apply. None of those assumptions transfer to a small molecule taken by mouth, and its regulatory record differs for exactly that reason.

Where the Biology Gets Interesting

Growth hormone secretion falls steadily from midpuberty onward, and that decline runs alongside the loss of muscle mass which defines sarcopenia. The observation is what made secretagogues interesting. Rather than giving growth hormone directly, which produces a flat level from outside the body, a secretagogue asks the pituitary to release its own in the pattern it normally uses.

Work in healthy older adults published in 1996 established that daily oral administration raises both growth hormone and IGF-1 and keeps that pulsatile pattern intact. This is a real finding and it is the most secure claim on the page. It is also a claim about an endocrine axis, not about a person's capacity.

The Mechanism, Without Overstating It

The molecule binds the growth hormone secretagogue receptor, GHS-R1a, which is the receptor for ghrelin. Agonism there drives pituitary release of growth hormone, and the liver responds to growth hormone by producing IGF-1. The measured rise in IGF-1 is therefore two steps downstream of where the compound actually acts.

Both steps are reliable and reproduce across the human studies behind this entry. That reliability is precisely what makes this compound a clean illustration of a common reasoning error. A mechanism that reliably moves a blood marker is often read as a mechanism that reliably moves an outcome, and those are different claims resting on different evidence.

The trials described below measured both in the same participants. The marker moved. The outcomes largely did not.

The entire human record is one company's development programme, and that programme stopped. Every trial cited here was run or authored by the company that developed the molecule. That is not on its own a reason to discount the findings, and the negative and safety results run against the sponsor's own interest, which if anything strengthens them. It does mean there is no independent modern human trial to weigh against them.

The functional endpoints were the point, and they were not met. Two trials in hip-fracture patients asked whether the endocrine change produced a change in what people could physically do. Neither showed it.

Long-term safety is unknown rather than reassuring. The longest exposure on record is two years in 65 healthy people, and the larger trial in a frailer population was halted before it finished. Nothing here describes what happens with use beyond that window, in younger people, or alongside anything else.

The regulator's stated concern is specific, and it is the reason this compound holds the status it does. The US Food and Drug Administration describes significant safety risks due to the potential for congestive heart failure in certain patients, citing a randomised placebo-controlled trial in hip-fracture recovery that was terminated early over a potential safety signal of congestive heart failure.

No event rate is given on this page. The trial abstract describes the signal as occurring in a limited number of patients and attaches no percentage to it, and the regulator's description attaches none either. Figures circulating elsewhere are not traceable to either document.

The second finding is metabolic, and it is easy to lose behind the cardiac one. Over twelve months of daily administration in healthy older adults, fasting blood glucose rose by roughly 0.3 mmol/L and insulin sensitivity decreased. Those participants were selected for being healthy. Among the smaller group who continued into a second year the glucose rise no longer reached significance, which complicates the picture rather than settling it: fewer people remained, the original placebo comparison no longer held, and the authors labelled that analysis exploratory.

A third finding sits in the same trial and is easy to miss, because its summary is gentler than its measurement. At twelve months, femoral neck bone mineral density rose slightly on placebo and fell slightly on the compound, and the difference between the two groups was small but statistically significant. The paper describes this as consistent with increased bone remodelling, which is a reasonable mechanistic reading of a marker that can move in either direction while turnover is elevated. The measured direction relative to placebo was downward, and both the measurement and the framing are given here so the reader can weigh them separately.

The useful way to read this compound is to hold two findings side by side, because both come from the same trials and the same participants.

Over twelve months in healthy older adults, fat-free mass rose while it fell on placebo, and body weight rose. Those are real body composition changes with clear statistical separation. In that same trial, the authors state plainly that the increased fat-free mass did not result in changes in strength or function.

In patients recovering from hip fracture, IGF-1 rose well above placebo with high statistical confidence, while stair-climbing power did not separate from placebo at all. Gait speed did improve, and that result should not be erased to make the story tidier. Several other functional measures showed no improvement, and the trial's own conclusion is that the IGF-1 rise was not paralleled by improvement in most functional performance measures.

Anyone reasoning from an IGF-1 number to an expected change in capacity is making precisely the inference these trials were built to test, and did not support.

Not a peptide. It is an orally active small molecule designed to mimic ghrelin, and the peptide label attaches to it only because it is sold through the same channels.

Not an approved medicine. No regulator has approved a drug product containing ibutamoren mesylate, and the development programme behind every trial on this page was discontinued.

Not banned by the US Food and Drug Administration. Category 2 under the compounding pathways means the agency published an identified safety concern while reviewing a nomination. It is not a scheduling action and it says nothing about the legality of possession.

Not permitted in tested sport. Ibutamoren is named on the World Anti-Doping Agency Prohibited List among growth hormone secretagogues, prohibited at all times and classed as a non-specified substance.

Not shown to improve strength or physical function. Three randomised trials measured functional endpoints, and the endocrine change did not carry through to them.

Not a protocol or personal-use guide. This page describes what a small and closed body of research measured, and gives no administration guidance.

This compound is a clean illustration of why evidence is tiered separately here rather than collapsed into a single impression. The mechanism is solid, the marker response reproduces, and the outcome evidence is absent. One rating covering all three would blur exactly the distinction a reader needs. Reading it honestly means holding the reliable endocrine finding and the unmet functional endpoints at the same time, and letting the regulator's published safety concern sit where it belongs rather than at the foot of the page.